Autolus Therapeutics to reduce workforce by approximately 13%

Autolus Therapeutics (AUTL) announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses. As part of this initiative, the company is implementing a reduction in force affecting approximately 13% of its workforce. “With a strong first year of launch in 2025 and good momentum into this year, we are now focused on optimizing our operating model and driving cost efficiency,” said Christian Itin, Autolus CEO. “These actions will enhance our margins, support scalable growth, and position Autolus for long-term value creation.” The actions are expected to reduce operating expenses by approximately $15M on an annualized basis beginning in 2027. Autolus reiterates full year 2026 Aucatzyl net product revenue of $120M-$135M, as well as an anticipated shift to positive gross margin in 2026.